An on-demand 30-minute discussion between three symposium co-chairs to highlight and summarize the most clinically relevant data from the International Ultmann Chicago Lymphoma Symposium (IUCLS), an annual conference dedicated solely to the science and clinical care of lymphoma. It was organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.
We were fortunate to have a multitude of the world’s experts in lymphoma speak at this year’s conference. The live audience was comprised of regional practicing oncologists, advanced nurse practitioners and physician assistants, residents, fellows, and the Chicago academic community that included five academic centers.
This is a certified continuing medical education (CME) activity that focuses on the biologic, diagnostic, and therapeutic aspects of Hodgkin lymphoma and non-Hodgkin lymphoma. This year’s conference was a 2-day live meeting to discuss recent updates in the care of patients with solid and hematologic malignancies.
Educational Partner: Bio Ascend
Medium: Interactive Module
Commercial Support: Support for this activity has been provided through educational grants from AbbVie Inc., Astra Zeneca, Genentech, Genmab, Janssen LP, MorphoSys, Novartis, and Seagen.
Expert Insights - 19th Annual International Ultmann Chicago Lymphoma Symposium
The University of Chicago via Independent
Overview
Syllabus
After completing this activity, the participant should be better able to:
- Compare and contrast the latest approaches to the treatment of patients with indolent and aggressive forms of non-Hodgkin lymphoma;
- Evaluate current and emerging approaches to the treatment of patients with Hodgkin lymphoma;
- Assess the latest clinical trial data of current and emerging CAR T-cells and cellular therapy for patients with hematologic malignancies, including important safety and efficacy data;
- Discuss patient and disease-related factors that impact the selection and sequencing of therapy for patients with CLL;
- Develop strategies to utilize the entire multidisciplinary team during the continuum of care of patients with lymphoma.
